XTX Topco Ltd Acquires 5,322 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

XTX Topco Ltd raised its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 159.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,665 shares of the company's stock after acquiring an additional 5,322 shares during the quarter. XTX Topco Ltd's holdings in Neurocrine Biosciences were worth $998,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC bought a new position in shares of Neurocrine Biosciences during the second quarter worth approximately $28,000. Innealta Capital LLC bought a new position in shares of Neurocrine Biosciences during the second quarter worth approximately $30,000. EdgeRock Capital LLC bought a new position in shares of Neurocrine Biosciences during the second quarter worth approximately $35,000. Blue Trust Inc. increased its holdings in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company's stock worth $40,000 after purchasing an additional 220 shares during the period. Finally, Plato Investment Management Ltd increased its holdings in shares of Neurocrine Biosciences by 44.1% during the second quarter. Plato Investment Management Ltd now owns 425 shares of the company's stock worth $59,000 after purchasing an additional 130 shares during the period. 92.59% of the stock is owned by institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now directly owns 15,449 shares of the company's stock, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.30% of the company's stock.

Neurocrine Biosciences Price Performance

NASDAQ NBIX traded down $0.74 during mid-day trading on Wednesday, reaching $128.22. 725,287 shares of the stock were exchanged, compared to its average volume of 868,371. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98. The stock has a 50 day simple moving average of $121.19 and a 200-day simple moving average of $130.80. The stock has a market cap of $12.98 billion, a P/E ratio of 34.38 and a beta of 0.34.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on NBIX shares. Royal Bank of Canada lowered their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating on the stock in a report on Friday, October 4th. BMO Capital Markets decreased their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating on the stock in a research note on Thursday, October 17th. HC Wainwright reissued a "buy" rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Needham & Company LLC reissued a "hold" rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. Finally, Raymond James reissued an "outperform" rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.